Tuesday, March 25, 2014

KinDex Pharmaceuticals Raises $5M

Seattle-based biopharmaceuticals developer KinDex Pharmaceuticals has raised $5M in a Series A funding. The funding was led by Polaris Partners. KinDex is specifically targeting Type 2 diabetes, using molecules which modulate regulatory networks associated with that disease. The company's also is looking at how those molecules are related to obesity. The company is led by Jeffrey Bland, Ph.D. More information »